Saadi Ryan H. 4

What Happened

• Ryan H. Saadi, CEO of Tevogen Bio Holdings Inc. (TVGN), was granted 1,220,000 restricted shares on July 10, 2026. The grant is recorded at $0.00 per share (award/grant), so no cash was paid by the reporting person at grant.
• This was an award (Form 4 transaction code A) of restricted stock rather than an open-market purchase or sale. The grant vests in four equal annual installments beginning on July 10, 2033, subject to continued service.

Key Details

• Transaction date: 2026-07-10
• Transaction type/code: Award/Grant (A)
• Shares granted: 1,220,000; Price reported: $0.00; Reported cash value at grant: $0
• Vesting: Ratably in four equal annual installments commencing July 10, 2033 (per footnote)
• Shares owned after transaction: Not specified in this filing
• Filing timeliness: Report lists the same report and transaction date (no late filing indicated in the report)
• Footnote: Grant made under Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan; vesting conditioned on continued service

Context

• Restricted stock grants are retention/compensation awards and do not represent an immediate market purchase or sale; their economic value to the insider depends on future vesting and any applicable tax withholdings at vesting.
• The long-delayed vesting start date (commencement in 2033) indicates a multi-year retention schedule; this is a contractual compensation detail rather than a near-term trading signal.